Mesa Laboratories MLAB Biopharmaceutical Development — Inventory Net
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mesa Laboratories in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The official record: Mesa Laboratories’s 10-K, filed June 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mesa Laboratories's biopharmaceutical development — inventory net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mesa Laboratories's biopharmaceutical development — inventory net?
- Mesa Laboratories (MLAB) reported biopharmaceutical development — inventory net of $6.51M in Q1 2026.
- How has Mesa Laboratories's biopharmaceutical development — inventory net changed year-over-year?
- Mesa Laboratories's biopharmaceutical development — inventory net increased by 32.0% year-over-year, from $4.93M to $6.51M.
- What is the long-term trend for Mesa Laboratories's biopharmaceutical development — inventory net?
- Over 2 years (2023 to 2026), Mesa Laboratories's biopharmaceutical development — inventory net has grown at a -4.5% compound annual growth rate (CAGR), from $26.36M to $24.06M.
- What does biopharmaceutical development — inventory net mean?
- Represents the net value of raw materials, work-in-progress, and finished goods held by the Biopharmaceutical Development segment after accounting for reserves. This metric reflects the segment's ability to manage supply chain efficiency and meet anticipated customer demand for life sciences tools. High levels may indicate potential overstocking or obsolescence risk, while low levels could signal supply constraints.